Skip to main content
Press Enter
BASF offers the world's largest portfolio of chemical raw materials for the pharmaceutical industry, ensuring the needs of our partners are always met. Every step of biopharmaceutical manufacturing requires high-quality raw materials delivered through a transparent, sustainable supply chain. BASF Biopharma Ingredients is committed to meeting your requirements for every ingredient we supply to the biologics industry. At BASF, we create excipients that are safe, effective, and convenient for your customers. Whether you’re developing orally disintegrating formulations that require taste-masking or modified release tablets, BASF has ingredients to deliver the precision you need, every time. At BASF, we offer a comprehensive range of cutting-edge solubilization polymers, and have an unparalleled understanding of the corresponding process technologies. BASF offers an unparalleled portfolio of excipients for topical formulations, enabling you with the tools to overcome formulation challenges. With products based on over 150 years of industry experience, BASF is committed to maintaining the highest level of quality across the product spectrum. BASF offers a broad portfolio of chemistries designed to simplify the product development process. Coating polymers are suitable for a variety of oral formulation challenges. As multifunctional excipients, ethoxylated solubilizers are known for their utility across a large range of dosage form classes. BASF's pharma grade lipid-based excipients are manufactured in GMP-compliant facilities with high quality and reliability in mind. BASF's portfolio of poloxamers are renown for their best-in-class quality. Consisting of a broad portfolio of polyethylene glycols (PEGs), BASF's portfolio of ethoxylated polymer-solubilizers is known for its versatility across a myriad of dosage forms. BASF offers a broad portfolio of functional excipients including our pharmaceutical grade polysorbate and sorbitan esters. Povidones, copovidones, and crospovidones are versatile materials that serve as the foundation of oral solid dosage forms. BASF's portfolio of solvents and co-solvents are suitable for a wide range of applications and processing methodologies. BASF offers a broad portfolio of brand families that are suitable for oral, topical, parenteral, and biologic applications. Coprocessed excipients are combination, all-in-one solutions. Kollicoat® coating polymers are suitable for a variety of oral formulation challenges. Kollicream® pharma grade solvents and emollients are manufactured in GMP-compliant facilities with high quality and reliability in mind. Kollidon® povidones, copovidones, and crospovidones are versatile materials that are most commonly used for solid oral dosage forms. Kolliphor® solubilizers, emulsifiers, co-emulsifiers, and surfactants enable the development of safe and effective formulations. Kollisolv® solubilizers and solvents are suitable for a wide range of applications and processing methodologies. Kolliwax® structuring agents, moisture barriers, and lubricants enable the formulation of various dosage forms. Novata® hard fats are structuring agents and matrix builders. Soluplus® is a novel solubilizer, crystallization inhibitor, and a matrix forming polymer. Explore this collection of resources to learn more about our innovative research and pharma solutions.

The New Frontier of Amorphous Solid Dispersions (Symposium Series)

The field of amorphous solid dispersions (ASDs) is experiencing a deepening of understanding and expansion of adoption. Thought-leaders and industry partners are rethinking established core principles of ASD formulation, exploring new way of accessing amorphous drug dosage forms, and articulating new guidance for optimal ASD design.

Key takeaways:

  • Updated design consideration and formulation guidance for ASD optimization
  • Fundamental dynamics of ASD stability and dissolution
  • Fresh manufacturing approaches to production of amorphous solids for improved drug solubility
D12 008 HMI header Amorphous Solid Dispersions (ASDs) produced by hot melt extrusion

BASF Expert and Host

Lindsay johnson

Dr. Lindsay Johnson, Global Technical Marketing Manager, leads the Solubilization Platform at BASF Pharma Solutions. In her role, Dr. Johnson manages global projects and teams to enable formulations of hydrophobic and highly crystalline active pharmaceutical ingredients through approaches like amorphous solid dispersions, self-emulsifying drug delivery systems, and softgel encapsulation. She also leads the parenterals portfolio for small molecule delivery through injection formulations. Dr. Johnson completed her Ph.D. on pharmaceutical excipients at the University of Minnesota. She has held a range of technical, innovation, and commercial roles within BASF, internationally and domestically.

LinkedIn Profile

Find a detailed overview of all six webinars here:

Amorphous solid dispersions, comprising a polymer and a poorly water-soluble drug, are an important formulation strategy for improving oral bioavailability. In spite of their increasing usage for drug delivery, factors impacting the rate of drug release from these formulations are not well understood. The mechanisms of release from ASDs of copovidone versus hypromellose acetate succinate will be compared and contrasted. The impact of drug loading on release performance will be considered in detail.

Our guest speaker, Professor Lynne S. Taylor is the Retter Distinguished Professor of Pharmacy in the Department of Industrial and Physical Pharmacy, Purdue University

Watch On-Demand

A large fraction of pharmaceutical products are administered as solids, with a growing interest in amorphous solid dispresions. This talk will focus on the material science of amorphous solid dispersion solids with a specific emphasis on their physical characterization. In drugs and excipients we investigate the polymorphic form, degree of crystallinity, and the nature and extent of interaction with water, to steer fundamental guidance on the stability and formulation of ASDs.

Our guest speaker Raj Suryanarayanan (Sury) is Professor and William and Mildred Peters Endowed Chair at the College of Pharmacy, University of Minnesota.

Watch On-Demand
Sury ASD Circle

Raj (Sury)
Professor and William & Mildred Peters Endowed Chair,
University of Minnesota

LinkedIn Profile

The pharmaceutical industry has a growing interest in continous techniques for producing drug-excipient particles, and twin-screw equipment can be applied to melt extrusion and granulation techniques. Defining the variables for twin-screw processes has a large impact on quality and properties of final product. Quality by Design can be applied to twin screw techniques, to define the optimal design space of a formulation.

Our guest speaker Dr. Michael A. Repka serves as the Distinguished Professor of the Department of Pharmaceutics & Drug Delivery and Director of the Pii Center for Pharmaceutical Technology at The University of Mississippi.

Watch On-Demand

Michael (Mika) Repka
Director of the Pii Center for PharmaceuticalTechnology, Distinguished Professor of Pharmaceuticals and Drug Delivery
University of Mississippi

LinkedIn Profile

Current routes to generate ASDs can result in high costs and present challenges for APIs with thermal sensitivity, organic solubility limitations and/or low glass transition temperatures. Co-precipitated ASD’s (cPAD) present a robust alternative to overcome these challenges and can be generated quickly and at low cost using existing drug substance processing infrastructure. The co-precipitation route also offers new means to influence particle properties; achieving architectures that can allow for dosage units with higher drug load and deliver material suitable for continuous direct compression.

Our guest speaker Luke Schenk leads the Particle Engineering Lab, at Merck & Co., Inc

Watch On-Demand
Schenk ASD Circle

Luke Schenk
Principle Scientist,
Merck & Co., Inc

LinkedIn Profile

Amorphous solid dispersions (ASD) through Fluid Bed Coating is an accessible route to readily processible ASD particles. This talk will explore the key considerations of formulation production for optimized ASD dissolution behavior.

Our guest speakers are Philippe TschoppHead of Business Development, and Norbert Pöllinger, Head of Technology Development Unit at Glatt Pharmaceutical Services.

Watch On-Demand
Tscopp ASD Circle

Philippe Tschopp
Head of Business Development at Advanced Drug Delivery Technologies,
Glatt Pharmaceuticals

LinkedIn Profile
Poellinger ASD Circle

Norbert Poellinger
Head Technology Development,
Glatt Pharmaceuticals

LinkedIn Profile

Formulations with high doses and/or poor solubility can be challenging to develop proper dissolution methods for. This talk with discuss some of the options available for these products including media optimization, different dissolution apparatuses, and higher volume modifications.

Our guest speaker Ken Boda is a Dissolution Product Specialist at Agilent.

Watch On-Demand
Boda ASD Circle

Ken Boda
Dissolution Product Specialist,
Agilent Technologies

LinkedIn Profile